ElectroCore
medical technology company
electroCore, Inc. (Nasdaq: ECOR) is a medical technology company based in Basking Ridge, New Jersey. electroCore was co-founded in 2005 by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD. The current chief executive officer is Daniel S. Goldberger. electroCore has one product called gammaCore, a non-invasive, commercially available product that uses vagus nerve stimulation.
History
The company was co-founded by JP Errico, Thomas J. Errico, MD, Charles Theofilos, MD, and Peter Staats, MD, in 2005.
In 2018, electroCore, Inc. went public with a $78 million IPO.
On March 27, 2020, electroCore announced a common stock purchase agreement of up to $25 million with Chicago-based institutional investor Lincoln Park Capital Fund, LLC.
In 2025, the company acquired NeuroMetrix, adding the Quell electrical nerve stimulation platform to its product portfolio.
Products
gammaCore Sapphire CV
In July 2020, the FDA gave an emergency COVID-19 authorization for gammaCore Sapphire CV, a vagus nerve stimulation device, aimed at reducing exacerbations in people potentially affected by the novel coronavirus and have difficulty breathing due to asthma.
Truvaga
A VNS product owned by Electrocore.
Begin with the source’s own compact description: “ElectroCore” is medical technology company. The dossier treats that line as a proposition to test through ElectroCore, medical and technology, not as a finished interpretation.
Why this record matters
The phrase “medical technology company” supplies a clear boundary for inquiry. It also exposes the unanswered questions: who defined that boundary, when it became stable and which sources sit outside it.
Datasets, specimens, observations and peer-reviewed methods provide the appropriate test for the technical claims summarized here. The source revision retrieved here is dated Jul 22, 2026. The linked authority identifier is Q65080611. None of the 0 selected statements returned an explicit reference. The first chronological checks are 2005, 2018, 2020 and 2025.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “ElectroCore”, its source revision and the description used here.
- Expand the search: follow ElectroCore primary sources, ElectroCore archive and ElectroCore research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “ElectroCore”?
- Has classification or technical consensus changed since the cited source?
- Is the terminology current, historical or disputed?
Search terms from this dossier
This entry incorporates text from “ElectroCore” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.